Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they do not cross the blood-brain barrier? We have sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We have also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinions against a patient’s true story. Will they match up?
Upon completion of this activity, participants should be better able to:
Arthritis Research UK Professor, Rheumatology
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases
R. J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Professor, Head of Rheumatology and Translational Research
Division of Infection and Immunity
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)
Cardiff University School of Medicine
Cardiff, UK
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
